We bring you the latest news from the healthcare about the health care in the United Kingdom. Do your have news for us? Contact the editor. Watch also this special movie.

vrijdag 16 juni 2017

The Lancet: [Articles] Ceritinib versus chemotherapy in patients with -rearranged non-small-cell lung cancer previous...

[Articles] Ceritinib versus chemotherapy in patients with -rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial
These findings show that patients derive significant clinical benefit from a more potent ALK inhibitor after failure of crizotinib, and establish ceritinib as a more efficacious treatment option compared with chemotherapy in this patient population.
Read more

[News] Olaparib provides benefit in metastatic breast cancer
New research suggests that, compared with single-agent chemotherapy, monotherapy with olaparib improves efficacy and safety in patients with HER2-negative breast cancer and a germline BRCA mutation.
Read more

[News] WHA passes resolution on cancer prevention and control
On May 31, 2017, the seventieth World Health Assembly (WHA) drew to an end. The most notable outcome was the election of Tedros Adhanom Ghebreyesus as the new WHO Director-General. But elsewhere on the agenda there were encouraging signs of increasing prominence for cancer care on the global stage. The member states passed a resolution on cancer prevention and control, and accepted updates to passages in the 2013–20 global plan for non-communicable diseases [NCDs], several of which pertained to cancer.
Read more

[News] 2017 ASCO Annual Meeting
David Michael Hyman (Memorial Sloan Kettering Cancer Center, New York, NY, USA) and colleagues reported the integrated dataset from one phase 2 and two phase 1 studies of larotrectinib—a selective pan-tropomyosin receptor kinase inhibitor—in children, adolescents, and adults with gene fusions involving the NTRK1, NTRK2, or NTRK3 genes (55 patients; age range 4 months to 76 years). The investigator-assessed overall response was 78% (95% CI 64–89) in 46 patients assessed so far, with responses noted in 12 of 13 tumour types.
Read more

[News] Adjuvant pertuzumab improves early breast cancer outcomes
New research suggests that in patients with operable HER2-positive breast cancer, treatment with pertuzumab, when given with trastuzumab and chemotherapy in the adjuvant setting, substantially improves invasivedisease-free survival when compared with treatment with placebo plus trastuzumab and chemotherapy.
Read more